<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283032</url>
  </required_header>
  <id_info>
    <org_study_id>PI18/01560</org_study_id>
    <nct_id>NCT04283032</nct_id>
  </id_info>
  <brief_title>Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis</brief_title>
  <acronym>RMPBX201801</acronym>
  <official_title>Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer With Different Approaches. Cost-effectiveness Analysis (RMP-BX 2018-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InvestigatorUrologyIBSAL</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Biomédica de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To establish if there are differences between an ultrasound-guided transrectal
      prostate biopsy (BPTE) and a transperineal prostatic biopsy (BPTP) with and without a
      multiparametric Magnetic Resonance (RMmp) in patients with clinical suspicion of prostate
      cancer (PC) to first prostatic biopsy in terms of:

        1. Rate of detection and diagnosis of prostate cancer.

        2. Aggressiveness of the detected tumors.

        3. Association of the marker [-2] proPSA and the prostate cancer health index (PHI) and
           microRNAs for the diagnosis of tumors.

        4. Adverse effects of the intervention and subjective perception of the patient: pain and
           degree of satisfaction, and impairment of quality of life.

        5. Cost-effectiveness analysis of the different intervention options.

      Study Design: Randomized, single-blind prospective clinical study to compare four schemes:
      RMmp + BPTE vs. BPTE 12 cylinders vs RMmp + BPTP vs BPTP 12 cylinders.

      Study population: Patients with clinical suspicion of prostate cancer with PSA between 3-20
      ng / mL and normal or abnormal rectal examination, candidates for a first prostate biopsy.

      Research techniques: BPTE standard of 12 cylinders compared to RMmp previous to BPTE vs BPTP
      of 12 cylinders compared to BPTP with previous RMmp.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Comparation between transrectal and transperineal prostatic biopsy with o without Magnetic Resonance</measure>
    <time_frame>6 months</time_frame>
    <description>Establish if there are differences between the transrectal and transperineal prostatic biopsy schemes in both cases with and without MRI, in patients with suspected clinical risk of prostate cancer (total PSA between 3 and 20 ng / mL, free PSA index / Total PSA less than 20% and normal or abnormal rectal examination) in terms of efficacy measured by the detection rate and tumor aggressiveness of the tumors detected, complication rates and cost analysis.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">628</enrollment>
  <condition>Establish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason Classification</condition>
  <condition>Establish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the Technique</condition>
  <condition>Establish the Efficacy Between the Four Schemes in Terms of the Patient's Subjective Perception Regarding Pain and Quality of Life</condition>
  <condition>Establish the Association of the Tumor Biomarker in the Early Detection and Aggressiveness of Tumors</condition>
  <condition>Establish the Possible Interaction Between Biomarkers and Resonance in Different Prostate Biopsy Models to Define Tumor Presence and / or Tumor Aggressiveness</condition>
  <condition>Establish the Possible Relationship Between the Expression Profiles of the microRNAs</condition>
  <condition>Establish if There Are Differences Between Transrectal and Transperineal Prostatic Biopsy Schemes in Both Cases With and Without MRI</condition>
  <arm_group>
    <arm_group_label>Multiparametric magnetic resonance + transrectal biopsy</arm_group_label>
    <description>The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transrectal biopsy (BPTE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiparametric magnetic resonance + transperineal biopsy</arm_group_label>
    <description>The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transperineal biopsy (BPTP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transrectal biopsy</arm_group_label>
    <description>The patient underwent a transrectal biopsy (BPTE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transperineal biopsy</arm_group_label>
    <description>The patient underwent a transperineal biopsy (BPTP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Multiparametric magnetic resonance</intervention_name>
    <description>MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).</description>
    <arm_group_label>Multiparametric magnetic resonance + transperineal biopsy</arm_group_label>
    <arm_group_label>Multiparametric magnetic resonance + transrectal biopsy</arm_group_label>
    <other_name>Transrectal biopsy</other_name>
    <other_name>Transperineal biopsy</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biomarker [-2] proPSA and PHI, microRNAs: miR-141, miR200C, hasa-miR-200b, miR-187,
      mir-188-5p, miR196b miR-151-3p, miR375, mir-16, miR25 and lec-7c.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected clinical risk of prostate cancer with total PSA values between 3
        and 20 ng / mL, free PSA index / total PSA less than 20% and normal or abnormal rectal
        examination, candidates for a first prostate biopsy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signature of informed consent prior to performing any of the specific procedures of
             the study

          -  Age between 50 * - 75 years (* 45 years, if family history)

          -  Patients with clinical suspicion of prostate cancer

          -  Indication of a first biopsy during the study period.

          -  Life expectancy greater than 10 years.

        Exclusion Criteria:

          -  Patients previously randomized in the present study.

          -  Patients submitted prior to a prostate biopsy.

          -  Patients with a previous diagnosis of prostate cancer and / or previous prostate
             surgery.

          -  Patients with a previous episode of acute prostatitis of infectious origin in the 3
             months prior to inclusion in the study.

          -  Patients with an active urinary tract infection and / or any previous pathology of
             severity in the 3 months prior to inclusion.

          -  Impossibility of performing transrectal or transperineal biopsy and / or magnetic
             resonance.

          -  Patients who have received hormonal treatment prior to androgen blockade in the 6
             months prior to inclusion in the study.

          -  History of other tumors.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francisco Gomez Veiga</last_name>
    <phone>923291100</phone>
    <phone_ext>55954</phone_ext>
    <email>fgveiga@telefonica.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Francisco Gómez Veiga</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Francisco Gomez Veiga, Dr.</last_name>
      <email>fgveiga@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Alvaro Virseda Rodríguez, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Gómez Veiga, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Herrero Polo, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuela Martín Izquierdo, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Rodríguez Antolin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Martín Hervas, Dra</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dalia Rashid Salim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Javier MartínVallejo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Alejandro Gomez Rivas, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Javier Castell Monsalve, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan José Fuertes Alija, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Heriberto Amon Sesmero, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesús Calleja Escudero, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria José Buj Pradilla, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Muñoz de Bustillo Llorente</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coral Manso Aparicio, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</investigator_affiliation>
    <investigator_full_name>InvestigatorUrologyIBSAL</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>PSA</keyword>
  <keyword>MMPm</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

